Home> Products> therapeutic regimen

{ "products": [ { "_id": "68c29ba02244c906e7790e2b", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TELAVINCE 300", "description": "TELAVINCE 300 is a high-quality antiviral medication containing Tenofovir Disoproxil Fumarate 300 mg, specifically formulated for the effective management of HIV-1 infection and chronic Hepatitis B in adults and adolescents. Manufactured under strict pharmaceutical standards, TELAVINCE 300 offers consistent, potent, and clinically proven antiviral action, helping to suppress viral replication and improve immune function.\n\nTenofovir Disoproxil Fumarate is a nucleotide reverse transcriptase inhibitor (NtRTI). It works by interfering with the enzyme reverse transcriptase, which is essential for viral replication in HIV and Hepatitis B viruses. By inhibiting this enzyme, TELAVINCE 300 reduces the amount of virus in the body, helping to prevent further immune system damage and liver complications.\n\n \nKey Indications:\n \n\nTELAVINCE 300 is indicated for:\n\nHIV-1 Infection: In combination with other antiretroviral agents for the treatment of HIV-1 in adults and adolescents (aged 12 years and older, weighing at least 35 kg).\n\nChronic Hepatitis B: For the treatment of chronic hepatitis B virus infection in adults and adolescents with compensated liver disease and evidence of active viral replication.\n\n \nMechanism of Action:\n \nTenofovir Disoproxil Fumarate is a prodrug of tenofovir, which, once absorbed and metabolized in the body, is converted into tenofovir diphosphate, the active form. Tenofovir diphosphate acts as a competitive inhibitor of reverse transcriptase, incorporating itself into the viral DNA chain and causing premature chain termination. This process disrupts the life cycle of the virus, significantly reducing its ability to multiply and spread.\n\n \nDosage and Administration:\n \n\nRecommended Dose for Adults and Adolescents (≥12 years, ≥35 kg): One tablet (300 mg) once daily, preferably with food.\n\nFor HIV Treatment: Administer in combination with other antiretroviral medications as per the treatment regimen.\n\nFor Chronic Hepatitis B: Monotherapy or as part of combination therapy, depending on patient condition and physician's assessment.\n\nDosage adjustments may be required in patients with renal impairment. Close monitoring is recommended for patients with existing kidney disease.\n\n \nKey Benefits of TELAVINCE 300:\n \n\nPotent Antiviral Action: Rapid and sustained suppression of HIV and HBV replication.\nOnce-Daily Dosing: Improves patient compliance and treatment adherence.\n\nBacked by Clinical Research: Proven efficacy in managing viral load and improving immune markers (CD4 count).\n\nTrusted Quality: Manufactured under GMP-certified facilities with stringent quality control processes.\n\nPart of First-Line Therapy: Recommended in various national and international treatment guidelines for HIV and Hepatitis B.\n\n \nSafety and Precautions:\n \n\nRenal Monitoring: Tenofovir may affect kidney function. Routine renal function tests are recommended before and during treatment.\n\nBone Mineral Density: Long-term use may reduce bone mineral density. Consider monitoring in patients at risk of osteopenia or osteoporosis.\n\nHepatic Flare: Discontinuation of therapy in hepatitis B patients may result in severe acute exacerbations. Liver function should be closely monitored post-treatment.\n\nLactic Acidosis and Hepatomegaly: Rare but serious side effects. Patients presenting symptoms such as abdominal pain, fatigue, or difficulty breathing should seek immediate medical attention.\n\n \n\nPossible Side Effects:\n \n\nMost patients tolerate TELAVINCE 300 well. However, some may experience:\n\nNausea\n\nDiarrhea\n\nHeadache\n\nFatigue\n\nRash\n\nDizziness\n\nDecreased bone mineral density\n\nRenal impairment (in rare cases)\n\nIf any side effects persist or worsen, consult a healthcare professional immediately.\n\n \nStorage Instructions:\n \n\nStore in a cool, dry place below 30°C.\n\nProtect from light and moisture.\n\nKeep out of reach of children.\n\n \n\nWhy Choose TELAVINCE 300?\n \n\nTELAVINCE 300 offers a dependable, clinically validated solution for the long-term management of HIV and Hepatitis B. With its once-daily dosing and proven effectiveness, TELAVINCE 300 is an ideal choice for patients and healthcare providers looking for quality, safety, and therapeutic reliability. It is manufactured by a trusted name in healthcare, ensuring every tablet meets global pharmaceutical standards.\n\n \nDisclaimer:\n \n\nThis product description is for informational purposes only and is not a substitute for professional medical advice. Always consult your doctor or healthcare provider before starting any medication.", "price": 1480.0, "discountamount": 444.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2179, "imageuri": "https://productimages.withfloats.com/actual/68c29ba3794abb27ab248d73.png", "tileimageuri": "https://productimages.withfloats.com/tile/68c29ba3794abb27ab248d73.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-09-11T09:51:28.508Z", "updatedon": "2025-09-11T09:51:28.508Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/telavince-300/2179", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Tenofovir Disoproxil Fumarate Tablets ip 300 mg", "category": "GENERAL RANGE", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "668e8611b9f7300708fe1240", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRIOGLIMITERIS 1/0.2 ", "description": "TRIOGLIMITERIS 1/0.2 \nVoglibose 0.2 mg, Glimepiride 1 mg & Metformin Hydrochloride 500 mg\nIntroduction\n\nTRIOGLIMITERIS 1/0.2 is a combination medication containing Voglibose, Glimepiride, and Metformin Hydrochloride. It is primarily used in the management of type 2 diabetes mellitus to improve glycemic control through different mechanisms of action targeting glucose metabolism.\n\nComposition\n\nVoglibose (0.2 mg): An alpha-glucosidase inhibitor that delays the digestion of carbohydrates in the intestine, thereby reducing postprandial blood glucose levels.\nGlimepiride (1 mg): A sulfonylurea derivative that stimulates insulin release from pancreatic beta cells, enhancing glucose uptake in peripheral tissues.\nMetformin Hydrochloride (500 mg): A biguanide that decreases hepatic glucose production, improves insulin sensitivity in peripheral tissues, and reduces intestinal glucose absorption.\nMechanism of Action\n\nTRIOGLIMITERIS 1/0.2 combines the actions of its components to achieve optimal glycemic control:\n\nVoglibose: Inhibits alpha-glucosidase enzymes in the intestine, delaying carbohydrate digestion and reducing the absorption of glucose after meals.\nGlimepiride: Stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner, thereby lowering blood glucose levels.\nMetformin Hydrochloride: Decreases hepatic glucose production through suppression of gluconeogenesis and enhances peripheral glucose uptake and utilization by improving insulin sensitivity.\nIndications\n\nTRIOGLIMITERIS 1/0.2 is indicated for:\n\nType 2 Diabetes Mellitus: Used to improve glycemic control in adults when diet, exercise, and monotherapy with metformin or sulfonylureas alone are not sufficient.\nDosage and Administration\n\nThe typical dosage of TRIOGLIMITERIS 1/0.2 is one tablet taken orally with meals, usually once or twice daily.\nDosage adjustments may be required based on individual patient response, blood glucose levels, and renal function.\nIt is essential to adhere to the prescribed dosage regimen to achieve optimal therapeutic outcomes.\nSide Effects\n\nCommon side effects of TRIOGLIMITERIS 1/0.2 may include:\n\nHypoglycemia (especially when used in combination with insulin or other antidiabetic medications)\nGastrointestinal disturbances (such as nausea, vomiting, diarrhea, or abdominal discomfort)\nWeight gain (mainly associated with sulfonylureas)\nMore severe side effects can include:\n\nAllergic reactions (rash, itching, swelling)\nLactic acidosis (rare but serious adverse effect associated with metformin use)\nHepatic dysfunction (monitor liver function tests periodically)\nPrecautions\n\nUse with caution in patients with renal impairment, hepatic dysfunction, or other significant medical conditions that may affect drug metabolism or excretion.\nRegular monitoring of blood glucose levels, renal function, and liver function is recommended during treatment with TRIOGLIMITERIS 1/0.2.\nAvoid use in patients with type 1 diabetes mellitus or diabetic ketoacidosis.\nDrug Interactions\n\nTRIOGLIMITERIS 1/0.2 may interact with other medications affecting blood glucose levels, such as insulin, other oral antidiabetic agents, or drugs that affect renal function or hepatic metabolism. Close monitoring and dose adjustments may be necessary.\nConclusion\n\nTRIOGLIMITERIS 1/0.2 provides a comprehensive approach to managing type 2 diabetes mellitus by combining Voglibose, Glimepiride, and Metformin Hydrochloride. This combination targets different aspects of glucose metabolism, enhancing insulin secretion, reducing hepatic glucose production, and delaying carbohydrate absorption in the intestine. Proper dosage, administration, and monitoring for side effects are essential to achieve and maintain optimal glycemic control in diabetic patients using TRIOGLIMITERIS 1/0.2. Consultation with a healthcare provider is recommended for personalized treatment plans and management of diabetes with this medication.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n", "price": 195.0, "discountamount": 58.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "500 mg", "0.2 mg", "one tablet", "Weight gain", "Glimepiride 1", "metformin use", "Proper dosage", "Glimepiride (1", "dosage regimen", "typical dosage", "renal function", "insulin release", "drug metabolism", "Lactic acidosis", "Close monitoring", "dose adjustments", "renal impairment", "diabetic patients", "insulin secretion", "different aspects", "Drug Interactions", "other medications", "Regular monitoring", "Dosage adjustments", "Allergic reactions", "peripheral tissues", "hepatic metabolism", "glucose metabolism", "insulin sensitivity", "healthcare provider", "Hepatic dysfunction", "Common side effects", "abdominal discomfort", "different mechanisms", "liver function tests", "diabetic ketoacidosis", "pancreatic beta cells", "combination medication", "carbohydrate digestion", "comprehensive approach", "serious adverse effect", "Metformin Hydrochloride", "carbohydrate absorption", "sulfonylurea derivative", "glucose-dependent manner", "optimal glycemic control", "type 1 diabetes mellitus", "type 2 diabetes mellitus", "More severe side effects", "alpha-glucosidase enzymes", "peripheral glucose uptake", "hepatic glucose production", "alpha-glucosidase inhibitor", "individual patient response", "personalized treatment plans", "optimal therapeutic outcomes", "Gastrointestinal disturbances", "intestinal glucose absorption", "other antidiabetic medications", "other oral antidiabetic agents", "postprandial blood glucose levels", "other significant medical conditions" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1939, "imageuri": "https://productimages.withfloats.com/actual/668e86143a68154e11e7d822.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/668e86143a68154e11e7d822.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-07-10T13:01:05.875Z", "updatedon": "2024-07-10T13:01:05.875Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trioglimiteris-1-0-2-/1939", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TRIOGLIMITERIS 1/0.2 ", "category": "DIABETIC RANGE", "tags": [ "glimepiride 1mg+metformin 500mg+voglibose 0.2 mg", "Glimepiride 2mg Metformin 500mg Voglibose 0.2 mg b", "glimepiride 2mg+metformin 500mg+voglibose 0.2 mg", "voglibose glimepiride & metformin hydrochloride (s", "voglibose glimepiride + metformin hydrochloride us", "glimepiride 1mg+metformin 500mg+voglibose 0.3 mg", "glimepiride 2mg+metformin 500mg+voglibose 0.2 mg g", "" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "666c10e66641561b0446977f", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VELAXFINE XR 37.5 ", "description": "VELAXFINE XR 37.5 \nVenlafaxine (37.5mg)\nIntroduction:\n\nVELAXFINE XR 37.5 contains Venlafaxine, an extended-release (XR) formulation designed to treat major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder (SAD), and panic disorder. With a dosage strength of 37.5mg, VELAXFINE XR 37.5 provides sustained therapeutic effects, significantly improving the quality of life for patients.\nKey Features and Benefits:\n\nAntidepressant Action:\n\nVELAXFINE XR 37.5 is a serotonin-norepinephrine reuptake inhibitor (SNRI). It works by increasing the levels of serotonin and norepinephrine in the brain, which helps improve mood and alleviate symptoms of depression.\nAnxiety Relief:\n\nVenlafaxine is effective in treating various anxiety disorders. It reduces the symptoms of anxiety, including excessive worry, restlessness, and physical symptoms such as palpitations and sweating.\nExtended-Release Formulation:\n\nThe extended-release formulation ensures a steady release of medication over 24 hours, providing consistent symptom relief and reducing the need for multiple daily doses. This improves adherence to the treatment regimen and enhances overall effectiveness.\nImproved Quality of Life:\n\nBy effectively managing symptoms of depression and anxiety, VELAXFINE XR 37.5 helps patients regain control of their lives, enhancing their ability to function socially and professionally.\nWell-Tolerated and Safe:\n\nVELAXFINE XR 37.5 is generally well-tolerated with a favorable safety profile, making it a reliable option for long-term management of depression and anxiety disorders.\nDosage and Administration:\n\nInitial Dosage for Depression and Anxiety:\n\nThe recommended starting dose of VELAXFINE XR 37.5 for adults is 37.5mg once daily, taken in the morning or evening. The dose may be increased gradually based on the patient's response and tolerability.\nMaintenance Dosage:\n\nThe usual maintenance dose ranges from 75mg to 225mg per day. Dosage adjustments should be made in increments of 37.5mg to 75mg at intervals of no less than 4 days.\nAdministration Instructions:\n\nVELAXFINE XR 37.5 capsules should be swallowed whole with water. They can be taken with or without food, although taking them with food may help reduce gastrointestinal discomfort.\nContinued Monitoring:\n\nRegular monitoring of symptoms, response to treatment, and potential side effects is essential during VELAXFINE XR 37.5 therapy to ensure therapeutic efficacy and patient safety.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\nhttps://www.sterisonline.com/product/velaxfine-xr-37-5-134393", "price": 58.0, "discountamount": 17.4, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "MDD", "SAD", "day", "GAD", "food", "life", "SNRI", "mood", "75mg", "need", "EMAIL", "water", "brain", "lives", "225mg", "37.5mg", "levels", "adults", "option", "control", "ability", "evening", "morning", "response", "patients", "Benefits", "sweating", "24 hours", "adherence", "intervals", "increments", "medication", "depression", "Venlafaxine", "information", "restlessness", "palpitations", "sterispharma", "sterisonline", "Introduction", "Key Features", "CALL/WHATSAPP", "starting dose", "panic disorder", "Initial Dosage", "patient safety", "steady release", "Anxiety Relief", "excessive worry", "dosage strength", "Improved Quality", "physical symptoms", "treatment regimen", "Regular monitoring", "Dosage adjustments", "Maintenance Dosage", "therapeutic efficacy", "Continued Monitoring", "multiple daily doses", "long-term management", "Antidepressant Action", "overall effectiveness", "usual maintenance dose", "potential side effects", "social anxiety disorder", "favorable safety profile", "VELAXFINE XR 37.5 therapy", "various anxiety disorders", "consistent symptom relief", "major depressive disorder", "VELAXFINE XR 37.5 capsules", "gastrointestinal discomfort", "Administration Instructions", "Extended-Release Formulation", "generalized anxiety disorder", "sustained therapeutic effects", "serotonin-norepinephrine reuptake inhibitor" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1910, "imageuri": "https://productimages.withfloats.com/actual/667d14c6ba7e6420d2a4fd30.png", "tileimageuri": "https://productimages.withfloats.com/tile/667d14c6ba7e6420d2a4fd30.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-14T09:44:06.065Z", "updatedon": "2024-06-27T07:29:09.447Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/velaxfine-xr-37-5-/1910", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "VELAXFINE XR 37.5 ", "category": "NEUROLOGY RANGE", "tags": [ "venlafaxine 37.5 mg", "VELAXFINE XR 37.5", "", "VELAXFINE XR 37.5 side effects", "venlafaxine 37.5mg used for", "venlafaxine urinary side effects" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "666c1007162db0236048bac5", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VALPOTREAT CR 500 ", "description": "VALPOTREAT CR 500 \nSodium Valproate CR 500 mg\nIntroduction:\n\nVALPOTREAT CR 500 contains Sodium Valproate, a potent anticonvulsant and mood stabilizer, in a controlled-release (CR) formulation. With a dosage strength of 500mg, VALPOTREAT CR 500 is designed to provide sustained therapeutic effects for managing epilepsy and bipolar disorder, significantly enhancing the quality of life for patients.\nKey Features and Benefits:\n\nAnticonvulsant Action:\n\nVALPOTREAT CR 500 is highly effective in treating various types of seizures, including generalized tonic-clonic seizures, absence seizures, and complex partial seizures. It increases gamma-aminobutyric acid (GABA) levels in the brain, helping stabilize neuronal activity and prevent seizure episodes.\nMood Stabilization:\n\nSodium Valproate is also used as a mood stabilizer for treating bipolar disorder. It helps control manic episodes and provides mood stability, reducing the frequency and severity of mood swings.\nControlled-Release Formulation:\n\nThe controlled-release formulation of VALPOTREAT CR 500 ensures a steady release of the medication over time, maintaining consistent blood levels and reducing the need for frequent dosing. This leads to better symptom control and improved adherence to the treatment regimen.\nWell-Tolerated and Safe:\n\nVALPOTREAT CR 500 is generally well-tolerated with a favorable safety profile, making it a reliable option for long-term management of epilepsy and bipolar disorder.\nDosage and Administration:\n\nInitial Dosage for Epilepsy:\n\nThe initial dose of VALPOTREAT CR 500 for adults typically starts at 500mg per day, divided into two doses. The dose can be gradually increased based on the patient's response and tolerability, with a usual maintenance dose ranging from 1000-2000mg per day.\nInitial Dosage for Bipolar Disorder:\n\nFor the treatment of bipolar disorder, the initial dose usually starts at 500mg per day, divided into two doses. The dose can be gradually increased based on clinical response, with a typical maintenance dose ranging from 1000-1500mg per day.\nAdministration Instructions:\n\nVALPOTREAT CR 500 tablets should be taken orally with water. They can be taken with or without food, although taking them with food may help reduce gastrointestinal discomfort.\nContinued Monitoring:\n\nRegular monitoring of blood levels, liver function, and overall health is essential during VALPOTREAT CR 500 therapy to ensure therapeutic efficacy and patient safety.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW \nhttps://www.sterisonline.com/product/valpotreat-cr-500-134217", "price": 121.18, "discountamount": 36.35, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "mg", "day", "life", "food", "time", "need", "EMAIL", "water", "brain", "adults", "option", "product", "quality", "epilepsy", "severity", "patients", "Benefits", "frequency", "two doses", "adherence", "medication", "mood swings", "information", "initial dose", "GABA) levels", "tolerability", "sterispharma", "Key Features", "Introduction", "sterisonline", "various types", "CALL/WHATSAPP", "liver function", "Initial Dosage", "patient safety", "overall health", "manic episodes", "steady release", "mood stability", "mood stabilizer", "symptom control", "frequent dosing", "dosage strength", "seizure episodes", "absence seizures", "bipolar disorder", "treatment regimen", "clinical response", "neuronal activity", "Mood Stabilization", "Regular monitoring", "Sodium Valproate CR", "Continued Monitoring", "long-term management", "therapeutic efficacy", "Anticonvulsant Action", "potent anticonvulsant", "usual maintenance dose", "gamma-aminobutyric acid", "consistent blood levels", "favorable safety profile", "complex partial seizures", "typical maintenance dose", "VALPOTREAT CR 500 therapy", "VALPOTREAT CR 500 tablets", "gastrointestinal discomfort", "Administration Instructions", "sustained therapeutic effects", "Controlled-Release Formulation", "generalized tonic-clonic seizures", "controlled-release (CR) formulation" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1909, "imageuri": "https://productimages.withfloats.com/actual/666c100b8c6c791fd3b72fe4.png", "tileimageuri": "https://productimages.withfloats.com/tile/666c100b8c6c791fd3b72fe4.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-14T09:40:23.921Z", "updatedon": "2024-06-26T05:53:21.154Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/valpotreat-cr-500-/1909", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "VALPOTREAT CR 500 ", "category": "NEUROLOGY RANGE", "tags": [ "Sodium Valproate CR 500 mg", "VALPOTREAT CR 500", "", "VALPOTREAT CR 500 price", "", "valprol cr 500 uses and side effects" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "666c0efb162db0236048ba8c", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VALPOTREAT CR 300 ", "description": "VALPOTREAT CR 300 \nSodium Valproate CR 300 mg\nIntroduction:\n\nVALPOTREAT CR 300 contains Sodium Valproate, a highly effective anticonvulsant and mood stabilizer, in a controlled-release (CR) formulation. With a dosage strength of 300mg, VALPOTREAT CR 300 is designed to provide sustained therapeutic effects for managing epilepsy and bipolar disorder, significantly enhancing the quality of life for patients.\nKey Features and Benefits:\n\nAnticonvulsant Action:\n\nVALPOTREAT CR 300 is highly effective in treating various types of seizures, including generalized tonic-clonic seizures, absence seizures, and complex partial seizures. It increases gamma-aminobutyric acid (GABA) levels in the brain, helping stabilize neuronal activity and prevent seizure episodes.\nMood Stabilization:\n\nSodium Valproate is also used as a mood stabilizer for treating bipolar disorder. It helps control manic episodes and provides mood stability, reducing the frequency and severity of mood swings.\nControlled-Release Formulation:\n\nThe controlled-release formulation of VALPOTREAT CR 300 ensures a steady release of the medication over time, maintaining consistent blood levels and reducing the need for frequent dosing. This leads to better symptom control and improved adherence to the treatment regimen.\nWell-Tolerated and Safe:\n\nVALPOTREAT CR 300 is generally well-tolerated with a favorable safety profile, making it a reliable option for long-term management of epilepsy and bipolar disorder.\nDosage and Administration:\n\nInitial Dosage for Epilepsy:\n\nThe initial dose of VALPOTREAT CR 300 for adults typically starts at 300-600mg per day, divided into two doses. The dose can be gradually increased based on the patient's response and tolerability, with a usual maintenance dose ranging from 1000-2000mg per day.\nInitial Dosage for Bipolar Disorder:\n\nFor the treatment of bipolar disorder, the initial dose usually starts at 300-600mg per day, divided into two doses. The dose can be gradually increased based on clinical response, with a typical maintenance dose ranging from 1000-1500mg per day.\nAdministration Instructions:\n\nVALPOTREAT CR 300 tablets should be taken orally with water. They can be taken with or without food, although taking them with food may help reduce gastrointestinal discomfort.\nContinued Monitoring:\n\nRegular monitoring of blood levels, liver function, and overall health is essential during VALPOTREAT CR 300 therapy to ensure therapeutic efficacy and patient safety.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\nhttps://www.sterisonline.com/product/valpotreat-cr-300-134219", "price": 78.0, "discountamount": 23.4, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "mg", "day", "life", "time", "food", "need", "EMAIL", "brain", "water", "adults", "option", "quality", "patients", "Benefits", "severity", "epilepsy", "adherence", "two doses", "frequency", "medication", "information", "mood swings", "Introduction", "initial dose", "sterisonline", "sterispharma", "tolerability", "GABA) levels", "Key Features", "various types", "CALL/WHATSAPP", "overall health", "Initial Dosage", "patient safety", "mood stability", "manic episodes", "steady release", "liver function", "mood stabilizer", "dosage strength", "symptom control", "frequent dosing", "bipolar disorder", "absence seizures", "seizure episodes", "neuronal activity", "treatment regimen", "clinical response", "Regular monitoring", "Mood Stabilization", "Sodium Valproate CR", "long-term management", "therapeutic efficacy", "Continued Monitoring", "Anticonvulsant Action", "usual maintenance dose", "gamma-aminobutyric acid", "consistent blood levels", "effective anticonvulsant", "complex partial seizures", "typical maintenance dose", "favorable safety profile", "VALPOTREAT CR 300 therapy", "VALPOTREAT CR 300 tablets", "Administration Instructions", "gastrointestinal discomfort", "sustained therapeutic effects", "Controlled-Release Formulation", "generalized tonic-clonic seizures" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1908, "imageuri": "https://productimages.withfloats.com/actual/666c0efef068be46bdec91c1.png", "tileimageuri": "https://productimages.withfloats.com/tile/666c0efef068be46bdec91c1.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-14T09:35:55.629Z", "updatedon": "2024-06-29T12:22:31.565Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/valpotreat-cr-300-/1908", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "VALPOTREAT CR 300 ", "category": "NEUROLOGY RANGE", "tags": [ "Sodium Valproate CR 300 mg", "VALPOTREAT CR 300", "", "VALPOTREAT CR 300", "valprol cr 300 side effects", "valprol cr 300 generic name", "valprol cr 300 dosage" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "666c0dc4a20cb421407442bd", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VALPOTREAT CR 200 ", "description": "VALPOTREAT CR 200 \nSodium Valproate CR 200 mg\nIntroduction:\n\nVALPOTREAT CR 200 contains Sodium Valproate, a widely used anticonvulsant and mood stabilizer, in a controlled-release (CR) formulation. With a dosage strength of 200mg, VALPOTREAT CR 200 is designed to provide sustained therapeutic effects for the management of epilepsy and bipolar disorder, improving the quality of life for patients.\nKey Features and Benefits:\n\nAnticonvulsant Action:\n\nVALPOTREAT CR 200 is highly effective in treating various types of seizures, including generalized tonic-clonic seizures, absence seizures, and complex partial seizures. It works by increasing the levels of gamma-aminobutyric acid (GABA) in the brain, which helps stabilize neuronal activity and prevent seizure episodes.\nMood Stabilization:\n\nSodium Valproate is also used as a mood stabilizer in the treatment of bipolar disorder. It helps control manic episodes and provides mood stability, reducing the frequency and severity of mood swings.\nControlled-Release Formulation:\n\nThe controlled-release formulation of VALPOTREAT CR 200 ensures a steady release of the medication over time, maintaining consistent blood levels and reducing the need for frequent dosing. This helps in achieving better symptom control and improving adherence to the treatment regimen.\nWell-Tolerated and Safe:\n\nVALPOTREAT CR 200 is generally well-tolerated with a favorable safety profile, making it a reliable option for long-term management of epilepsy and bipolar disorder.\nDosage and Administration:\n\nInitial Dosage for Epilepsy:\n\nThe initial dose of VALPOTREAT CR 200 for adults typically starts at 200-400mg per day, divided into two doses. The dose can be gradually increased based on the patient's response and tolerability, with a usual maintenance dose ranging from 1000-2000mg per day.\nInitial Dosage for Bipolar Disorder:\n\nFor the treatment of bipolar disorder, the initial dose usually starts at 200-400mg per day, divided into two doses. The dose can be gradually increased based on clinical response, with a typical maintenance dose ranging from 1000-1500mg per day.\nAdministration Instructions:\n\nVALPOTREAT CR 200 tablets should be taken orally with water. They can be taken with or without food, although taking them with food may help reduce gastrointestinal discomfort.\nContinued Monitoring:\n\nRegular monitoring of blood levels, liver function, and overall health is essential during VALPOTREAT CR 200 therapy to ensure therapeutic efficacy and patient safety.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\nhttps://www.sterisonline.com/product/valpotreat-cr-200-134218", "price": 75.0, "discountamount": 22.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "mg", "day", "need", "life", "GABA", "food", "time", "EMAIL", "water", "brain", "adults", "option", "product", "quality", "severity", "epilepsy", "Benefits", "patients", "adherence", "frequency", "two doses", "medication", "information", "mood swings", "Introduction", "initial dose", "Key Features", "tolerability", "sterispharma", "sterisonline", "CALL/WHATSAPP", "various types", "patient safety", "Initial Dosage", "overall health", "steady release", "liver function", "mood stability", "manic episodes", "dosage strength", "mood stabilizer", "symptom control", "frequent dosing", "absence seizures", "bipolar disorder", "seizure episodes", "clinical response", "treatment regimen", "neuronal activity", "Regular monitoring", "Mood Stabilization", "Sodium Valproate CR", "therapeutic efficacy", "long-term management", "Continued Monitoring", "Anticonvulsant Action", "usual maintenance dose", "consistent blood levels", "gamma-aminobutyric acid", "typical maintenance dose", "complex partial seizures", "favorable safety profile", "VALPOTREAT CR 200 therapy", "VALPOTREAT CR 200 tablets", "gastrointestinal discomfort", "Administration Instructions", "sustained therapeutic effects", "Controlled-Release Formulation", "generalized tonic-clonic seizures", "controlled-release (CR) formulation" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1907, "imageuri": "https://productimages.withfloats.com/actual/666c0dc8c9162f54a15a020e.png", "tileimageuri": "https://productimages.withfloats.com/tile/666c0dc8c9162f54a15a020e.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-14T09:30:44.587Z", "updatedon": "2024-06-26T09:16:37.475Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/valpotreat-cr-200-/1907", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "VALPOTREAT CR 200 ", "category": "NEUROLOGY RANGE", "tags": [ "VALPOTREAT CR 200", "Sodium Valproate CR 200 mg", "valpotreat cr 200 uses in hindi", "valprol cr 200 uses in hindi", "valpotreat cr 200 expiry date", "valpotreat" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "666be6b8aa93342004eef58f", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "ROPINPRIME 2 ", "description": "ROPINPRIME 2 \nRopinirole (2mg)\nIntroduction:\n\nRopinprime 2 is a medication containing Ropinirole, a potent dopamine agonist used primarily for treating Parkinson's disease and restless legs syndrome (RLS). With a dosage strength of 2mg, Ropinprime 2 is designed to effectively alleviate symptoms by mimicking dopamine's action in the brain, thus improving motor function and enhancing the quality of life for patients.\nKey Features and Benefits:\n\nDopamine Agonist:\n\nRopinprime 2 acts as a dopamine agonist, stimulating dopamine receptors in the brain. This action helps reduce motor symptoms associated with Parkinson's disease, such as tremors, stiffness, and bradykinesia (slowed movement).\nImproved Motor Function:\n\nBy enhancing dopaminergic activity, Ropinprime 2 aids in improving overall motor function, allowing patients to perform daily activities with greater ease and independence.\nRestless Legs Syndrome Relief:\n\nRopinprime 2 is also effective in managing the symptoms of restless legs syndrome (RLS), a condition characterized by an uncontrollable urge to move the legs, often accompanied by uncomfortable sensations. Ropinirole helps reduce these symptoms, improving sleep quality and overall comfort.\nFlexible Dosing:\n\nThe 2mg dosage strength allows for flexible dosing regimens, enabling healthcare providers to tailor treatment plans based on individual patient needs, symptom severity, and response to therapy.\nDosage and Administration:\n\nInitial Dosage for Parkinson's Disease:\n\nThe recommended starting dose of Ropinprime 2 for Parkinson's disease is typically 0.25mg taken three times daily. The dose can be gradually increased based on clinical response and tolerability. Maintenance doses usually range from 1mg to 8mg per day, divided into multiple doses.\nInitial Dosage for Restless Legs Syndrome:\n\nFor RLS, the initial dose is usually 0.25mg taken once daily, 1 to 3 hours before bedtime. The dose may be increased to 0.5mg and then to 1mg, depending on patient response and symptom control.\nAdministration Instructions:\n\nSwallow Ropinprime 2 tablets whole with water, with or without food. Taking the medication with food may help reduce the likelihood of nausea.\nContinued Monitoring:\n\nRegular monitoring of symptoms, motor function, and potential side effects is essential during Ropinprime 2 therapy to ensure therapeutic efficacy and patient safety.\n\n\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW \nhttps://www.sterisonline.com/product/ropinprime-2-133629", "price": 135.0, "discountamount": 40.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "day", "RLS", "1mg", "8mg", "life", "aids", "food", "brain", "Order", "EMAIL", "0.5mg", "water", "0.25mg", "action", "nausea", "bedtime", "disease", "tremors", "patients", "Benefits", "condition", "Parkinson", "stiffness", "Ropinirole", "likelihood", "medication", "information", "Introduction", "bradykinesia", "independence", "tolerability", "initial dose", "sterisonline", "sterispharma", "greater ease", "Key Features", "CALL/WHATSAPP", "sleep quality", "starting dose", "motor symptoms", "patient safety", "multiple doses", "Initial Dosage", "overall comfort", "treatment plans", "slowed movement", "symptom control", "patient response", "symptom severity", "daily activities", "clinical response", "Maintenance doses", "Regular monitoring", "dopamine receptors", "uncontrollable urge", "2mg dosage strength", "Ropinprime 2 therapy", "healthcare providers", "therapeutic efficacy", "Continued Monitoring", "dopaminergic activity", "overall motor function", "potential side effects", "potent dopamine agonist", "Improved Motor Function", "uncomfortable sensations", "flexible dosing regimens", "individual patient needs", "Administration Instructions", "Swallow Ropinprime 2 tablets", "Restless Legs Syndrome Relief" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1895, "imageuri": "https://productimages.withfloats.com/actual/667d15dbce74849f89cdd68a.png", "tileimageuri": "https://productimages.withfloats.com/tile/667d15dbce74849f89cdd68a.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-14T06:44:08.261Z", "updatedon": "2024-06-27T07:33:46.566Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/ropinprime-2-/1895", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "ROPINPRIME 2 ", "category": "NEUROLOGY RANGE", "tags": [ "Ropinirole (2mg)", "ROPINPRIME 2", "ropinirole side effects", "ropinirole side effects: weight gain", "ropinirole side effects in elderly" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "666be5a070774b1f84f699ad", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "ROPINPRIME 1 ", "description": "ROPINPRIME 1 \nRopinirole (1mg)\nIntroduction:\n\nRopinprime 1 contains Ropinirole, a potent dopamine agonist used primarily to treat Parkinson's disease and restless legs syndrome (RLS). With a dosage strength of 1mg, Ropinprime 1 is designed to alleviate symptoms by mimicking the action of dopamine in the brain, thereby improving motor function and enhancing the quality of life for patients.\nKey Features and Benefits:\n\nDopamine Agonist:\n\nRopinprime 1 acts as a dopamine agonist, stimulating dopamine receptors in the brain. This mechanism helps reduce the motor symptoms associated with Parkinson's disease, such as tremors, stiffness, and bradykinesia (slowed movement).\nImproved Motor Function:\n\nBy enhancing dopaminergic activity, Ropinprime 1 aids in improving overall motor function, allowing patients to perform daily activities with greater ease and independence.\nRestless Legs Syndrome Relief:\n\nRopinprime 1 is also effective in managing the symptoms of restless legs syndrome (RLS), a condition characterized by an uncontrollable urge to move the legs, often accompanied by uncomfortable sensations. Ropinirole helps reduce these symptoms, improving sleep quality and overall comfort.\nFlexible Dosing:\n\nThe 1mg dosage strength provides flexibility in dosing regimens, enabling healthcare providers to tailor treatment plans based on individual patient needs, symptom severity, and response to therapy.\nDosage and Administration:\n\nInitial Dosage for Parkinson's Disease:\n\nThe recommended starting dose of Ropinprime 1 for Parkinson's disease is typically 0.25mg taken three times daily. The dose can be gradually increased based on clinical response and tolerability. Maintenance doses usually range from 1mg to 8mg per day, divided into multiple doses.\nInitial Dosage for Restless Legs Syndrome:\n\nFor RLS, the initial dose is usually 0.25mg taken once daily, 1 to 3 hours before bedtime. The dose may be increased to 0.5mg and then to 1mg, depending on patient response and symptom control.\nAdministration Instructions:\n\nSwallow Ropinprime 1 tablets whole with water, with or without food. Taking the medication with food may help reduce the likelihood of nausea.\nContinued Monitoring:\n\nRegular monitoring of symptoms, motor function, and potential side effects is essential during Ropinprime 1 therapy to ensure therapeutic efficacy and patient safety.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\nhttps://www.sterisonline.com/product/ropinprime-1-133628", "price": 124.0, "discountamount": 37.2, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "RLS", "day", "8mg", "life", "food", "EMAIL", "water", "0.5mg", "Order", "brain", "nausea", "action", "0.25mg", "bedtime", "disease", "tremors", "patients", "Benefits", "movement", "mechanism", "condition", "Parkinson", "stiffness", "medication", "likelihood", "Ropinirole", "flexibility", "information", "bradykinesia", "independence", "tolerability", "Introduction", "sterisonline", "initial dose", "sterispharma", "Key Features", "greater ease", "CALL/WHATSAPP", "starting dose", "sleep quality", "motor symptoms", "Initial Dosage", "multiple doses", "patient safety", "symptom control", "treatment plans", "dosing regimens", "Flexible Dosing", "overall comfort", "symptom severity", "patient response", "daily activities", "Maintenance doses", "clinical response", "dopamine receptors", "Regular monitoring", "1mg dosage strength", "uncontrollable urge", "Continued Monitoring", "therapeutic efficacy", "healthcare providers", "Ropinprime 1 therapy", "dopaminergic activity", "overall motor function", "potential side effects", "potent dopamine agonist", "Improved Motor Function", "individual patient needs", "uncomfortable sensations", "Administration Instructions", "Swallow Ropinprime 1 tablets", "Restless Legs Syndrome Relief" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1894, "imageuri": "https://productimages.withfloats.com/actual/666be5a4475de163fe91643d.jpg", "tileimageuri": "https://productimages.withfloats.com/tile/666be5a4475de163fe91643d.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-14T06:39:28.983Z", "updatedon": "2024-06-26T07:04:00.123Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/ropinprime-1-/1894", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "ROPINPRIME 1 ", "category": "NEUROLOGY RANGE", "tags": [ "ROPINPRIME 1", "ropinirole side effects in elderly", "ropinirole side effects", "ropinirole warnings" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "666be4714cb45413344ec323", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "ROPINPRIME 0.5 ", "description": "ROPINPRIME 0.5 \nRopinirole (0.5mg)\nIntroduction:\n\nRopinprime 0.5 contains Ropinirole, a dopamine agonist used primarily for treating Parkinson's disease and restless legs syndrome (RLS). With a dosage strength of 0.5mg, Ropinprime 0.5 aims to alleviate symptoms by mimicking the action of dopamine in the brain, thus improving motor function and enhancing quality of life for patients.\nKey Features and Benefits:\n\nDopamine Agonist:\n\nRopinprime 0.5 acts as a dopamine agonist, directly stimulating dopamine receptors in the brain. This action helps reduce the motor symptoms associated with Parkinson's disease, such as tremors, stiffness, and bradykinesia (slowed movement).\nImproved Motor Function:\n\nBy enhancing dopaminergic activity, Ropinprime 0.5 aids in improving overall motor function, allowing patients to perform daily activities with greater ease and independence.\nRestless Legs Syndrome Relief:\n\nRopinprime 0.5 is also effective in managing the symptoms of restless legs syndrome (RLS), a condition characterized by an uncontrollable urge to move the legs, often accompanied by uncomfortable sensations. Ropinirole helps reduce these symptoms, improving sleep quality and overall comfort.\nFlexible Dosing:\n\nThe 0.5mg dosage strength allows for flexible dosing regimens, enabling healthcare providers to tailor treatment plans based on individual patient needs, symptom severity, and response to therapy.\nDosage and Administration:\n\nInitial Dosage:\nThe recommended starting dose of Ropinprime 0.5 for Parkinson's disease is typically 0.25mg taken three times daily. The dose can be gradually increased based on clinical response and tolerability.\nRestless Legs Syndrome:\nFor RLS, the initial dose is usually 0.25mg taken once daily, 1 to 3 hours before bedtime. Dosage may be adjusted according to patient response and symptom control.\nAdministration Instructions:\nSwallow Ropinprime 0.5 tablets whole with water, with or without food. Taking the medication with food may help reduce the likelihood of nausea.\nContinued Monitoring:\nRegular monitoring of symptoms, motor function, and potential side effects is essential during Ropinprime 0.5 therapy to ensure therapeutic efficacy and patient safety.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW \nhttps://www.sterisonline.com/product/ropinprime-0-5-133627", "price": 60.0, "discountamount": 18.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "RLS", "aids", "life", "food", "Order", "water", "brain", "EMAIL", "0.25mg", "nausea", "action", "bedtime", "disease", "tremors", "patients", "Benefits", "stiffness", "condition", "Parkinson", "Ropinirole", "likelihood", "medication", "information", "Introduction", "initial dose", "independence", "greater ease", "tolerability", "Key Features", "sterispharma", "bradykinesia", "sterisonline", "CALL/WHATSAPP", "sleep quality", "starting dose", "patient safety", "motor symptoms", "Initial Dosage", "overall comfort", "treatment plans", "slowed movement", "symptom control", "dopamine agonist", "patient response", "daily activities", "symptom severity", "clinical response", "Regular monitoring", "dopamine receptors", "uncontrollable urge", "Continued Monitoring", "healthcare providers", "therapeutic efficacy", "0.5mg dosage strength", "dopaminergic activity", "Ropinprime 0.5 therapy", "overall motor function", "potential side effects", "Improved Motor Function", "individual patient needs", "uncomfortable sensations", "flexible dosing regimens", "Administration Instructions", "Restless Legs Syndrome Relief", "Swallow Ropinprime 0.5 tablets" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1893, "imageuri": "https://productimages.withfloats.com/actual/666be475844f2600246a0b63.jpg", "tileimageuri": "https://productimages.withfloats.com/tile/666be475844f2600246a0b63.jpg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-14T06:34:25.708Z", "updatedon": "2024-06-26T07:04:57.853Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/ropinprime-0-5-/1893", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "ROPINPRIME 0.5 ", "category": "NEUROLOGY RANGE", "tags": [ "ropinprime 0.5 mg tablet 10", "ropinprime 0.5 mg tablet uses", "ropin 0.5 injection", "ropinirole warnings", "ropinirole side effects" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }